NEW YORK (GenomeWeb) – Sunnyvale, California-based InSilixa has received funding to develop a point-of-care rapid molecular diagnostic assay for oral human papillomavirus detection, the company announced today.

The $224,764 Phase I Small Business Innovation Research grant was awarded by the National Institutes of Health.

The assay is "a potential new tool to screen oral specimens such as saliva for cancer-causing HPV types and to risk stratify those persons found to be positive,” Gary Schoolnik, chief medical officer of InSilixa, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.